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Summary
 
Eosinophils are the source of various immunoregulatory cytokines, but the membrane mole-
cules involved in their secretion have not been clearly identified. Here we show that peripheral
blood eosinophils from hypereosinophilic patients could express membrane CD86 but not
CD80. The T cell costimulatory molecule CD28 is also detected on the eosinophil surface.
CD28 ligation but not CD86 ligation resulted in interleukin (IL)-2 and interferon (IFN)-
 
g
 
 se-
cretion by eosinophils, whereas IL-4, IL-5, and IL-10 were not detected. In contrast to T cells
requiring two signals for effective stimulation, CD28 ligation alone was sufficient for optimal
eosinophil activation. Eosinophil-derived IL-2 and IFN-
 
g
 
 were biologically active, as superna-
tants from anti-CD28–treated cells were able to induce CTLL-2 proliferation and major histo-
compatibility complex class II expression on the colon carcinoma cell line Colo 205, respec-
tively. Addition of secretory immunoglobulin (Ig)A–anti-IgA complexes, which could induce
the release of IL-10, very significantly inhibited both CD28-mediated IL-2 and IFN-
 
g
 
 release.
These results suggest that the release of type 1 (IFN-
 
g
 
 and IL-2) versus type 2 cytokines by
eosinophils is not only differential but also dependent on cross-regulatory signals. They confirm
that through activation of costimulatory molecules, eosinophils could function as an immuno-
regulatory cell involved in the release of both type 1 and type 2 cytokines.
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P
 
roverbially implicated in parasitic infections and allergic
manifestations, eosinophils are in fact associated with
most of the inflammatory or infectious disorders. Their
major function was thought to be restricted to degranula-
tion and release of highly cytotoxic proteins. However, in
addition to being cytotoxic mediators, eosinophils have the
capacity to produce a large number of cytokines, including
pro- and antiinflammatory cytokines, growth factors, and
chemokines (1). The demonstration that eosinophils from
patients or donors could synthesize and release IL-5 (2, 3),
IL-4 (4, 5), and IL-10 (6, 7) suggested that eosinophils
could also participate in the regulation of the Th2 pathway
of the immune response. Eosinophilia, frequently associ-
ated with increased IgE levels, appears mainly linked to a
Th2 response. However, the clinical heterogeneity of hy-
pereosinophilic syndromes, including patients with and
without increased IgE levels (8), led us to suggest that eosin-
ophils could be also associated with a Th1 response. Pre-
liminary studies have indicated that eosinophils from hy-
pereosinophilic patients stained positively for IFN-
 
g 
 
(9),
while IL-2 and more recently IL-12 were also detected
within eosinophils (10, 11), indicating that eosinophils
could play important roles in the modulation of the im-
mune response, in both its type 1 and type 2 pathways.
Until now, very few studies have reported the secretion
of these various cytokines by eosinophils, and they were
mainly based on the use of nonphysiological stimuli such as
calcium ionophores or serum-coated particles (5). The
more convincing results on cytokine secretion were ob-
tained after activation of eosinophils with IgA immune
complexes, which induce the release of IL-5 (3) and IL-4
(4) but do not seem to be able to induce the secretion of
Th1 cytokines.
In addition to Fc receptors involved in the release of
granule proteins, eosinophils express a large variety of
membrane molecules, including MHC class II (12), CD40
(13), and CD40L (14), which participate in their cross-talk
with T and B cells. Previous studies have shown that eosin-
ophils can function as APCs (15, 16). Thus, it was of inter-
est to investigate whether eosinophils could express other
costimulatory molecules potentially involved in cytokine
release.
It is now well accepted that the major T cell costimula-
tory pathway involves the CD28 molecule (17). After en- 
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gagement of the TCR with a class II (or I) MHC molecule
on the APC, IL-2 production and IL-2 receptor expression
are initiated; the second signal provided by the CD28/B7
interaction stabilizes IL-2 mRNA and increases IL-2 secre-
tion, resulting in T cell proliferation and clonal expansion
(18, 19). CD28 seems to be expressed only on T cells, and
its expression increased after T cell activation. CD28 inter-
acts with molecules of the B7 family present mainly at the
surface of murine and human APCs, as well as on activated
T and B cells (20). Two members have been identified:
B7-1 (CD80) and B7-2 (CD86). Most APCs require stim-
uli for the induction of CD80 and CD86 expression, but
CD86 is induced more rapidly than CD80 (21). It has been
suggested that CD80-expressing APCs provided the co-
stimulus for type 1 cells and CD86-expressing APCs for
type 2 cells (22).
In this work we showed, by flow cytometry, that puri-
fied eosinophils from eosinophilic patients express mem-
brane CD86 but not CD80. In addition, the presence of
CD28 was also detected on eosinophil membrane. After
CD28 ligation, eosinophils were able to secrete IL-2 and
IFN-
 
g
 
, with biological activities, whereas no secretion of
IL-4, IL-5, or IL-10 was detected. During the course of
these experiments, it was shown that the addition of IgA–
anti-IgA complexes was able to inhibit the release of IL-2
and IFN-
 
g
 
 mediated by CD28 ligation. In contrast, IgA
complexes induced the release of IL-10, which in turn was
inhibited by the addition of anti-CD28 Abs. These results
suggest differential pathways leading to the release of type 1
(IFN-
 
g
 
 and IL-2) versus type 2 (IL-10) cytokines by eosin-
ophils. The demonstration that eosinophils could express
costimulatory molecules involved in the selective secretion
of type 1 cytokines suggests a new function for eosinophils
in the regulation of the immune response.
 
Materials and Methods
 
Eosinophil Donors.
 
A total of 21 different patients with hyper-
eosinophilia associated with skin diseases, allergy, hypereosino-
philic syndromes, or myeloproliferative disorders were selected
for this study, after informed consent. Five normal donors were
also included in the study. The characteristics of eosinophil do-
nors and eosinophil preparations are summarized in Table I.
 
Reagents.
 
Anti–human CD16 and CD3 magnetic beads and
the magnetic cell separation system (MACS
 
®
 
) were purchased
from Miltenyi Biotec. Percoll was obtained from Amersham
Pharmacia Biotech. RPMI 1640 medium, glutamine, penicillin,
streptomycin, and FCS were obtained from GIBCO BRL. The
FITC-conjugated and nonconjugated anti-CD28 (clone B-T3),
anti-CD86, and mouse IgG1 mAbs were purchased from Dia-
clone. The FITC-conjugated and nonconjugated anti-CD80
were from Immunotech. The anti-CD28 Ab (9.3 mAb) was a
gift from Dr. C. June (University of Pennsylvania School of
Medicine, Philadelphia, PA). The anti-CD28 (clone CD28.2)
and the anti–mouse IgG F(ab
 
9
 
)
 
2
 
 were from Sigma Chemical Co.
The FITC-conjugated anti–IFN-
 
g
 
, anti–IL-2, and anti–IL-10
mAbs and isotype-matched Abs were obtained from Diaclone.
The nonconjugated anti–IL-2 was from Genzyme Corp. The
anti–IFN-
 
g
 
, anti–IL-10, and isotype control Abs were from Dia-
clone. The recombinant human (rh)IL-2 was purchased from
Boehringer Mannheim, and the rhIFN-
 
g
 
 was from Diaclone.
Human secretory IgA was obtained from Sigma Chemical Co.
Anti–human IgA mAb was from Immunotech. The Quantum
Simply Cellular quantification kit and the mouse alkaline phos-
phatase anti-alkaline phosphatase (APAAP)
 
1
 
 detection system
were purchased from Dako. The goat anti-CD28 (C-20) was
from Santa Cruz Biotechnology. The mouse IgG control Ab and
the horseradish peroxidase (HRP)-conjugated anti–goat IgG
were obtained from Jackson ImmunoResearch Laboratories.
 
Eosinophil Purification.
 
Eosinophils were isolated from the
venous blood of patients by the method described previously (23)
with minor modifications, using immunomagnetic beads and the
magnetic cell separation system (MACS
 
®
 
). Diluted whole blood
(1:1) was layered onto a Percoll gradient (
 
d
 
 5 
 
1.082 g/liter) and
 
1
 
Abbreviations used in this paper:
 
 APAAP, alkaline phosphatase anti-alkaline
phosphatase; HRP, horseradish peroxidase; LDH, lactate dehydrogenase.
 
Table I.
 
Summary of the Characteristics of Eosinophil Donors
 
Donors Diagnosis
Patient
group Eosinophilia
 
*
 
Percentage of
eosinophils
 
‡
 
1 Allergy A 1,780 99
2 Allergy A 1,200 98
3 Churg-Strauss A 1,550 90
4 Churg-Strauss A 13,800 99
5 Allergy A 2,070 100
6 Eczema SK 1,900 100
7 Eczema SK 1,000 95
8 Erythroderma SK 1,400 97.5
9 Angioma SK 8,050 99.5
10 Psoriasis SK 2,100 94
11 Psoriasis SK 750 96.5
12 HES HD 1,370 97.5
13 HES HD 1,610 97
14 Lymphoma HD 5,900 95
15 HES HD 3,540 98
16 HES HD 4,000 98
17 HES HD 9,900 99.5
18 Allergy A 1,100 97
19 HES HD 43,700 99.5
20 Eczema SK 2,400 98
21 Angioma SK 3,100 97
22 Normal donor ND
 
,
 
300 97.5
23 Normal donor ND
 
,
 
300 85
24 Normal donor ND
 
,
 
300 96
25 Normal donor ND
 
,
 
300 83
26 Normal donor ND
 
,
 
300 93.5
A, allergy; HD, hematological disorders; HES, hypereosinophilic syn-
dromes; ND, normal donors; SK, skin diseases.
 
*
 
Absolute numbers of eosinophils/mm
 
3
 
.
 
‡
 
Percent purity of eosinophil preparation after purification on MACS
 
®
 
. 
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centrifuged at 1,800 rpm for 20 min. The granulocyte pellet,
mainly neutrophils and eosinophils, was harvested and depleted
of erythrocytes by hypotonic saline lysis. In brief, the granulocyte
pellet was incubated for 30 min at 4
 
8
 
C with anti-CD16 and anti-
CD3 immunomagnetic beads in order to remove neutrophils
and contaminating lymphocytes, respectively. Eosinophils were
eluted by passage of the cells through the field of a permanent
magnet. After isolation, eosinophil preparations were cytocentri-
fuged, and the cytospins were stained with May-Grünwald-Giemsa
(RAL 555; Rieux). The purity of eosinophil preparations usually
reached 
 
.
 
97% for patients (Table I).
 
Flow Cytometric Analysis.
 
Freshly purified eosinophils were
resuspended at 3 
 
3 
 
10
 
6
 
/ml in PBS/1% BSA. Aliquots of 50 
 
m
 
l
were incubated with FITC-conjugated anti-CD28, anti-CD80,
or anti-CD86 mAb or FITC-conjugated isotype-matched Ab at a
final concentration of 5 
 
m
 
g/ml for 1 h at 4
 
8
 
C in round-bottomed
96-well plates. After two washes in PBS, the cells were resus-
pended in PBS/0.5% BSA before analysis.
For intracellular staining, eosinophils were fixed with 2%
paraformaldehyde in PBS for 10 min. After washing in PBS, the
cells were resuspended at 4 
 
3 
 
10
 
6
 
/ml in PBS containing 1% BSA
and 0.5% saponin (permeabilization buffer) for 10 min at room
temperature. The samples were then preincubated for 10 min
with 5 
 
m
 
l normal mouse serum in order to block nonspecific
binding, and were incubated for an additional 30 min with
FITC-conjugated anticytokine mAb or isotype-matched Ab at a
final concentration of 5 
 
m
 
g/ml in permeabilization buffer. After
washing in permeabilization buffer, followed by washing in PBS,
the cells were resuspended in PBS/0.5% BSA. Samples were ana-
lyzed on a FACSCalibur™ using CellQuest software (Becton
Dickinson). 10
 
4
 
 events were usually acquired per sample. Thresh-
olds were set on control stains (included for every sample at every
time point).
The antigen density at the cell surface was quantified with the
Quantum Simply Cellular quantification kit, in which the me-
dian values of fluorescence intensity were converted into Ab
binding capacity (ABC) units using calibrating microbeads with
specific Ab binding capacity. In parallel to staining of the samples,
the goat anti–mouse Ig–coated microbeads were incubated with
FITC-conjugated anti-CD28, anti-CD86, or FITC-conjugated
isotype-matched Ab. The lower quantification limit for CD28
and CD86 expression was 7,300 ABC units.
 
Immunocytochemistry.
 
Cytospins of freshly purified eosino-
phils were fixed in acetone at 
 
2
 
20
 
8
 
C for 10 min. After air drying,
slides were stored at 
 
2
 
20
 
8
 
C until use. The APAAP method was
used for immunostaining. In brief, after saturation with 10% nor-
mal rabbit serum diluted in Tris-buffered saline (TBS) containing
1% BSA, cytospins were incubated with anti–human cytokine or
isotype control mAbs at 30 
 
m
 
g/ml in TBS/1% BSA overnight at
4
 
8
 
C. The slides were washed twice for 15 min in TBS, then in-
cubated with rabbit anti–mouse Igs (1:25) in TBS/1% BSA for 1 h
at room temperature. After washing as above, they were incu-
bated with APAAP complex (1:40) for 1 h, and the reaction was
developed with New Fuchsin substrate (Dako). The slides were
counterstained with Mayer’s hematoxylin and mounted with
Fluoroprep (BioMérieux). For IFN-
 
g
 
 and IL-10 detection, the
intensity of the reaction was increased by performing a second
round of APAAP reaction.
 
Immunoprecipitation and Immunoblotting.
 
Freshly purified eosin-
ophils (2.5 
 
3 
 
10
 
7
 
) and Jurkat cells (2 
 
3 
 
10
 
7
 
) were lysed on ice for
30 min with 0.5% Triton X-100 in borate-buffered saline (BBS)
buffer, pH 8.0, containing 1 mM PMSF, 1 
 
m
 
g/ml aprotinin, 1
 
m
 
g/ml pepstatin, 1 
 
m
 
g/ml leupeptin. The lysates were centri-
 
fuged at 12,000 
 
g
 
 at 4
 
8
 
C. Supernatants were sequentially incu-
bated with 30 
 
m
 
l of protein G–Sepharose beads (1 h, 4
 
8
 
C; Sigma
Chemical Co.), 30 
 
m
 
l protein G–Sepharose-bound mouse IgG
(1 h, 4
 
8
 
C), and then 30 
 
m
 
l protein G–Sepharose-bound anti-
CD28 (9.3 mAb) for 2 h at 4
 
8
 
C. The beads were washed five
times with lysis buffer, and immune complexes were resuspended
in reducing Laemmli sample buffer. The samples were heated to
95
 
8
 
C for 5 min and then run on 8% SDS-PAGE. The separated
proteins were transferred onto nitrocellulose membrane. The
membrane was incubated in a blocking buffer containing 5%
BSA and 0.1% Tween 20 in PBS for 2 h, followed by incubation
with a goat anti-CD28 at a 1:500 dilution in PBS/1% BSA/0.1%
Tween 20 for 2 h. After washing in PBS/0.1% Tween 20, the
blot was incubated for 1 h with HRP-conjugated anti–goat Ab at
a 1:5,000 dilution in PBS/0.1% Tween 20. Immunoblot signals
were detected using Renaissance Western Plus reagent from
NEN Life Sciences.
 
Cell Activation.
 
Culture medium consisted of RPMI 1640
supplemented with 10% heat-inactivated FCS, 2 mM 
 
l
 
-glutamine,
100 IU/ml penicillin, 100 
 
m
 
g/ml streptomycin. Cross-linking
experiments were performed in 24-well culture plates. Wells
were first coated with 40 
 
m
 
g/ml anti–mouse IgG F(ab
 
9
 
)
 
2
 
 for 2 h
at 37
 
8
 
C in 5% CO
 
2
 
. After washing, wells were incubated with 10
 
m
 
g/ml mouse anti-CD28 (B-T3 mAb), anti-CD86 mAb, or iso-
type-matched control mAb for 2 h at 37
 
8
 
C in 5% CO
 
2
 
. The
wells were then washed twice with PBS, and 2 
 
3 
 
10
 
6
 
 eosinophils
in 1 ml culture medium were added per well. After 18 h culture,
supernatants were collected and analyzed for cytokine secretion.
For stimulation with IgA and anti-IgA, highly purified eosino-
phils were first incubated with secretory IgA at a final concentra-
tion of 15 
 
m
 
g/ml. After 1 h incubation at 37
 
8
 
C, cells were trans-
ferred into either 24-well plates or anti-CD28–coated plates and
stimulated with 20 
 
m
 
g/ml anti-IgA mAb at 37
 
8
 
C in 5% CO
 
2
 
. Af-
ter 18 h culture, cell viability was determined by trypan blue ex-
clusion, and supernatants were collected and analyzed for cytokine
secretion.
 
Lactate Dehydrogenase Assay.
 
Eosinophil cytolysis was fol-
lowed by measuring the cytoplasmic marker lactate dehydroge-
nase (LDH) in the supernatants of eosinophils incubated for 18 h
with medium alone, immobilized anti-CD28 mAb, IgA immune
complexes, or with Triton X-100 as positive control. LDH was
evaluated by colorimetric assay (Boehringer Mannheim) (24).
 
Cytokine Measurements.
 
IL-2, IFN-
 
g
 
, and IL-10 were assayed
in eosinophil supernatants using specific ELISA kits (Diaclone)
according to the manufacturer’s instructions. The lower detection
limit was 10 pg/ml for IL-2, 5 pg/ml for IFN-
 
g
 
, and 5 pg/ml for
IL-10.
 
Determination of Biological Activities of Eosinophil-derived IL-2 and
IFN-
 
g
 
.
 
The biological activity of IL-2 released in eosinophil
supernatants was measured by the conventional CTLL-2 assay. In
brief, 10
 
4
 
 CTLL-2 cells per well were cultured in 96-well micro-
titer plates with serial dilutions of rhIL-2 or eosinophil superna-
tants (at a 50% dilution) in a final volume of 100 
 
m
 
l, for 24 h at
37
 
8
 
C in 5% CO
 
2
 
. 6 h before harvesting, cells were pulsed with
0.5 
 
m
 
Ci [
 
3
 
H]thymidine. All assays were performed in duplicate.
To determine the biological activity of IFN-
 
g
 
 released by
eosinophils, the capacity of IFN-
 
g
 
 to induce expression of MHC
class II (HLA-DR) protein on the human colon carcinoma cell
line Colo 205 (American Type Culture Collection) was used
(25). In brief, 2 
 
3 
 
10
 
4
 
 cells in a final volume of 200 
 
m
 
l were cul-
tured in 96-well plates in the presence of variable concentrations
of rhIFN-
 
g
 
 (0.1–10 U/ml) or eosinophil supernatants (at a dilu-
tion of 20%), in the presence or absence of neutralizing anti– 
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IFN-
 
g
 
 mAb (Diaclone). After 48 h culture at 37
 
8
 
C in 5% CO
 
2
 
,
cells were harvested and analyzed for HLA-DR expression by
flow cytometry, using PE-conjugated anti–HLA-DR mAb (Bec-
ton Dickinson).
 
Results and Discussion
Detection of Intracellular Cytokines in Human Eosinophils.
Freshly isolated eosinophils from eosinophilic patients were
used to examine the intracellular expression of IL-2, IFN-g,
and IL-10. Results from flow cytofluorimetric analysis pre-
sented in Fig. 1 A, which illustrates one representative ex-
periment, showed that human eosinophils could express
IL-2 and IFN-g, as well as IL-10. The specificity of intra-
cellular staining was controlled by incubation of the cells
with FITC-conjugated mAb in the presence of an excess of
the corresponding recombinant cytokine. For the three cy-
tokines under study, this procedure led to an almost total
inhibition of the signal (data not shown).
To confirm the intracellular expression of the cytokines
observed by flow cytometry analysis, cytospin preparations
of purified eosinophils were incubated with anticytokine
mAb from different clones than those used for flow cytom-
etry. The preparations were then processed for immuno-
histochemical analysis using the APAAP method, followed
by counterstaining with hematoxylin. As shown in Fig. 1
B, eosinophils exhibited positive staining for IL-2, IFN-g,
and IL-10. No staining was observed when cells were incu-
bated with an irrelevant isotype control Ab.
Until now, most studies have examined the cytokine
content of human eosinophils by nonquantitative ap-
proaches such as reverse transcription PCR for mRNA ex-
pression and immunocytochemistry or electron microscopy
for intracellular protein detection (2–5). By using cytofluo-
rometry, we showed clearly that a large proportion of hu-
man eosinophils have the capacity to express both type 1
(IL-2 and IFN-g) and type 2 (IL-10) cytokines.
Detection of CD86 and CD28 on Human Eosinophils. To
investigate the expression by eosinophils of the costimula-
tory molecules CD80, CD86, and CD28, freshly isolated
human eosinophils from 17 hypereosinophilic patients and
5 normal donors were stained with FITC-conjugated anti-
CD80, anti-CD86, or anti-CD28 (B-T3) mAb or isotype-
matched Ab and analyzed by flow cytometry. Results pre-
sented in Fig. 2 A show clearly that, among the B7 family,
eosinophils could express CD86 (B7-2) but not CD80 (B7-
1). Unexpectedly, the presence of the T cell–associated
molecule CD28 was also detected on eosinophils. Both
CD86 and CD28 were detected in all donors, but their ex-
pression was variable among individual patients, ranging
from 6 to 63% and from 4 to 25%, respectively (Fig. 2 B).
For both CD86 and CD28, the mean fluorescence in-
tensity (MFI), which reflects the level of binding of the
Abs, was low, suggesting a low level of membrane expres-
sion. Indeed, using a technique for direct quantification of
cell surface molecules, we detected 8,003 6 231 and 9,039 6
644 Ab binding sites per cell for CD28 and CD86, respec-
tively (n 5 4). Preliminary experiments performed on a
limited number of healthy donors indicate that normal
eosinophils could also express membrane CD86 and CD28,
but at a lower level (Fig. 2 B). Due to the small number in
each group of eosinophilic patients, it was difficult to ob-
Figure 1. Intracellular pro-
duction of IL-2, IFN-g, and
IL-10 by human eosinophils.
Freshly purified eosinophils (pu-
rity .98%) were analyzed by di-
rect immunofluorescence flow
cytometry (A) and immunocy-
tochemistry (B). (A) After fixa-
tion and permeabilization, the
cells were stained with FITC-
conjugated anti–IL-2, anti–IFN-g,
or anti–IL-10 (bold line) or iso-
type-matched Ab (dashed line),
as described in Materials and
Methods. Cell fluorescence was
measured using a FACSCali-
bur™ equipped with CellQuest
software, and thresholds were set
according to the isotype-
matched controls. A total of 104
cells were usually acquired. (B)
Cytospins of eosinophil prepara-
tion were incubated with anti–
IL-2, anti–IFN-g, anti–IL-10
mAb or isotype-matched Ab (in-
set), and the staining was revealed
using the APAAP detection sys-
tem and New Fuchsin colora-
tion. Cells were counterstained
with Mayer’s hematoxylin (orig-
inal magnification: 3100).491 Woerly et al.
serve any correlation with the etiology of the disease, as re-
ported for other membrane molecules (26).
To further confirm the expression of CD28 by human
eosinophils, immunoprecipitation followed by Western
blotting was performed. As shown in Fig. 3, a 50-kD pro-
tein was specifically immunoprecipitated with anti-CD28
mAb (9.3 mAb), whereas no band appeared when lysates
were immunoprecipitated with mouse IgG–bound Sepharose
beads. Under the same conditions, immunoprecipitation
using Jurkat cells as positive control showed a much stron-
ger band, indicating that CD28 expression in human eosin-
ophils is lower than in T cells, as already suggested by flow
cytometry (Fig. 2). Although CD28 is a homodimeric mol-
ecule, comprising a 44-kD subunit, the variation in molecular
mass observed between eosinophils and Jurkat cells likely
arises as a result of different glycosylation patterns. Such an
observation has already been made for a T cell leukemia
cell line (27).
Secretion of IL-2 and IFN-g after CD28 Cross-linking.
The demonstration that human peripheral blood eosino-
phils could express CD86 and CD28 led us to investigate
the functional significance of these costimulatory molecules
in eosinophil activation. Since it has been reported that
CD28 ligation in T cells resulted in IL-2 secretion and pro-
liferation, cross-linking experiments of purified eosinophils
with immobilized anti-CD28 or anti-CD86 mAb were
performed, and the release of cytokines was assayed in su-
pernatants. Eosinophils from six individual patients were
added to plates coated with anti-CD28 or anti-CD86 mAb,
and supernatants were collected after 18 h and analyzed. As
shown in Fig. 4, CD28 ligation induced IL-2 and IFN-g
secretion, whereas in the same activation conditions, no re-
lease of IL-4, IL-5, or IL-10 was detected (data not shown).
Contrary to T cells, stimulation via the CD28 molecule did
not appear to require a second signal for optimal eosinophil
stimulation, since the addition to anti-CD28 mAb of vari-
ous stimuli such as LPS, Ca21 ionophores, or PMA did not
lead to an increase in cytokine secretion (data not shown).
Fig. 4 shows that the secretion of IL-2 and IFN-g was vari-
able according to individual patients, with a massive pro-
duction of IL-2 (up to 700 pg/ml) observed for some do-
nors after CD28 stimulation. The levels of IFN-g were
lower than those of IL-2, with a maximum of 180 pg/ml
and a minimum of 30 pg/ml. It is interesting to notice that
the maximum secretion for IL-2 and IFN-g was reached
for the same eosinophil donors. In contrast to CD28 cross-
linking and although CD86 was expressed on these eosino-
phil preparations, CD86 ligation did not induce the secre-
tion of IL-2 or IFN-g (Fig. 4) or the release of IL-4, IL-5,
or IL-10. Nonstimulated eosinophils or eosinophils cross-
linked with isotype-matched Ab produced very low
amounts of IL-2 and IFN-g (,10 pg/ml). In parallel to the
anti-CD28 mAb from clone B-T3, we also used anti-
CD28 mAb from a different clone. Immobilized 9.3 mAb
was also able to induce IL-2 and IFN-g secretion, although
to a lesser extent (data not shown).
To exclude the possibility that some lymphocytes could
contaminate the eosinophil preparation and therefore be
responsible for the IL-2 and IFN-g secretion observed,
lymphocytes isolated from hypereosinophilic patients were
stimulated in the same conditions as purified eosinophils
with immobilized anti-CD28. No secretion of IL-2 and
Figure 2. Expression of costimulatory molecules of the CD28/B7 fam-
ily by human eosinophils. (A) Representative profiles of anti-CD80, anti-
CD86, and anti-CD28 mAb binding to freshly purified human eosino-
phils. Cells were stained with FITC-conjugated anti-CD80, anti-CD86,
or anti-CD28 mAb (bold line) or isotype-matched control Ab (dotted
line). Samples were analyzed by flow cytometry using a FACSCalibur™
equipped with CellQuest software. A total of 104 cells were usually ac-
quired. (B) Variable expression of CD86 and CD28 by individual pa-
tients. Data are presented as percentage of positive cells from 17 eosino-
philic patients (Table I, donors 1–17) and 5 normal donors (Table I,
donors 22–26). The donors were classified as follows: A, allergy; SK, skin
diseases; HD, hematological disorders; ND, normal donors. The percent-
age of positive cells was calculated by subtracting the isotype control from
the specific signal.
Figure 3. CD28 expression in human eosinophils. Western blot analy-
sis of freshly purified eosinophils (Eosino., 2.5 3 107) and Jurkat T cells (2 3
107) after sequential immunoprecipitation with unconjugated Sepharose
beads (preclear.), mouse IgG control Ab (norm.mIgG), and anti-CD28
mAb (anti-CD28 [9.3 mAb]). Material was run on 8% SDS-PAGE and
transferred to nitrocellulose. Membrane was probed with anti-CD28 Ab.492 CD28-mediated Release of IL-2 and IFN-g by Eosinophils
IFN-g could be detected, in the absence of additional
CD3-TCR triggering.
These findings indicate that activation of the costimula-
tory molecule CD28 expressed by human eosinophils is
able to induce the release of IL-2 and IFN-g. In contrast,
CD86 cross-linking did not induce a similar cytokine re-
lease by eosinophils.
Biological Activity of IL-2 and IFN-g Released by Eosino-
phils. In spite of the numerous studies published on cy-
tokine secretion by eosinophils, very few have evaluated
the biological activity of the cytokines released. Therefore,
appropriate bioassays were performed in order to evaluate
the functional activity of IL-2 and IFN-g in eosinophil su-
pernatants. The biological activity of IL-2 in the superna-
tants of CD28-activated eosinophils was evaluated in a pro-
liferation assay using the IL-2–dependent mouse cytotoxic
T cell line CTLL-2. The results presented in Fig. 5 indicate
that eosinophil supernatants induced the proliferation of
CTLL-2 cells, with large variations according to individual
eosinophil donors. Comparison with the results obtained
for purified rhIL-2 (Fig. 5 A) indicated that between 100 and
250 pg/ml of biologically active IL-2 could be detected in
eosinophil supernatants after CD28 ligation (Fig. 5 B).
Similarly, the bioactivity of IFN-g secreted by eosino-
phils was assessed according to its capacity to enhance
MHC class II expression on the Colo 205 cell line (25). In
parallel with the effect of rhIFN-g (Fig. 5 C), supernatants
derived from eosinophils activated upon CD28 ligation
were able to induce MHC class II, as shown by flow cyto-
metric analysis (Fig. 5 D). This effect was significantly in-
hibited by the addition of neutralizing anti–IFN-g mAb
(Fig. 5 D). In contrast, supernatants from eosinophils incu-
bated with immobilized anti–mouse IgG1 did not induce
the release of biologically active IFN-g.
Cross-regulation of Cytokine Secretion by Secretory IgA and
Anti-CD28. Since previous studies have shown that
secretory IgA immune complexes could induce eosinophil
degranulation, as well as IL-5 and IL-4 secretion (3, 4), we
have investigated whether the activation of eosinophils
with IgA could influence the CD28-induced cytokine re-
lease. As shown in Fig. 6, the addition of secretory IgA and
anti-IgA mAb together with anti-CD28 ligation strongly
inhibited the secretion of IL-2 (82 6 32% inhibition) and
IFN-g (74 6 23% inhibition) (n 5 3). These results indi-
Figure 4. Release of IL-2 and IFN-g by eosinophils after stimulation
with anti-CD28 mAb. For stimulation, wells of a 24-well plate were first
coated with 40 mg/ml anti–mouse IgG F(ab9)2, followed by 10 mg/ml
anti-CD28, anti-CD86, or isotype mouse IgG1 control Ab. After wash-
ing, freshly purified eosinophils (2 3 106 in 1 ml) were added per well.
After 18 h, supernatants were harvested and analyzed by ELISA. Grey
bars, immobilized anti-CD28 mAb–stimulated eosinophils; black bars,
immobilized anti-CD86 mAb–stimulated eosinophils; hatched bars,
mouse IgG1 control. Results were obtained from six individual patients
(Table I, donors 2, 8, 11, 16, 19, and 21).
Figure 5. Biological activity of IL-2 and IFN-g released by CD28-
activated eosinophils. (A and B) Detection of the proliferative activity
of IL-2 released by eosinophils on an IL-2–dependent cell line. Supernatants
collected from eosinophils (2 3 106/ml) stimulated with immobilized
anti-CD28 mAb or isotype control Ab for 18 h were able to sustain the
IL-2–dependent growth of the mouse cytotoxic T cell line CTLL-2
(American Type Culture Collection). The CTLL-2 cells were cultured in
the presence of rhIL-2 (A) or eosinophil supernatants (50% dilution; B)
for 24 h. Proliferation was measured by [3H]thymidine incorporation.
Each supernatant obtained from individual patients (Table I, donors 2, 11,
and 16) was assayed in duplicate. Results are expressed as proliferation in-
dex 6 SD, according to the following formula: proliferation index 5
dpm (eosinophils stimulated with anti-CD28 mAb)/dpm (eosinophils
stimulated with isotype control mAb). An index .3 was considered sig-
nificant. (C and D) Supernatants collected from eosinophils (2 3 106/ml)
stimulated with cross-linked anti-CD28 mAb or isotype control Ab for
18 h were assayed for IFN-g–induced MHC class II expression on Colo
205 cells. The Colo 205 cells were cultured in the presence of rhIFN-g
(C) or eosinophil supernatants (20% dilution; D). After 48 h, cells were
harvested and stained with a PE-conjugated anti–HLA-DR mAb or an
isotype-matched Ab and examined by flow cytometry. Specificity of the
bioassay was controlled by adding a neutralizing anti–IFN-g mAb to the
culture. Cell fluorescence was measured using a FACSCalibur™ flow cy-
tometer, and data were analyzed using CellQuest software. Data are pre-
sented as mean 6 SD from three different experiments (Table I, donors 2,
8, and 16).493 Woerly et al.
cate that secretory IgA–dependent activation of eosinophils
could induce a downregulation of the CD28 activation
pathway and prevent type 1 cytokine secretion.
To ascertain that the secretion or lack of secretion of cy-
tokines observed was not due to eosinophil death during
incubation, the release of LDH, a sensitive marker of cell
lysis (24), was measured in the supernatants of eosinophils
incubated with medium alone, immobilized anti-CD28, or
IgA–anti-IgA for 18 h. Depending on the patient, LDH re-
lease ranged from 13.1 6 1.5 to 32.2 6 4% compared with
a positive control represented by Triton X-100–lysed cells
(data not shown). The trypan blue exclusion method con-
firmed z96% cell viability at the end of the culture, in all
conditions. These results indicate that cytokine secretion
after CD28 and/or IgA complex ligation is not due to a
massive cytolysis.
To further elucidate the mechanism of inhibition of the
release of type 1 cytokines by IgA complexes, we evaluated
the role of IL-10, which is the more potent cytokine in-
volved in the negative regulation of type 1 cytokines. Acti-
vation of eosinophils with IgA–anti-IgA induced IL-10 se-
cretion, in contrast to CD28 ligation (Fig. 6). These results
favor the view that IgA complexes, by inducing IL-10 re-
lease, could have an inhibitory effect on CD28-mediated
release of IFN-g and IL-2. Moreover, the addition of im-
mobilized anti-CD28 at the time of IgA cross-linking led
to a significant inhibition of IL-10 secretion (89 6 19% in-
hibition; Fig. 6). These results indicate that IFN-g and IL-2
on one hand, and IL-10 on the other, could be released by
human eosinophils upon different signaling pathways.
In conclusion, our results showed that human eosino-
phils can express both CD86, classically expressed by
APCs, and its CD28 ligand, a potent signaling molecule
expressed by T cells. The detection on eosinophils of T
cell–associated molecules has already been shown for CD4
(28). The coexpression, on the same cell population, of
two molecules acting as ligands for each other has also been
reported, for example by eosinophils in the case of CD40–
CD40L (13, 14) and by T cells which could, in addition to
CD28, express B7 (29). Further experiments are needed to
ascertain whether such pairs of molecules are really ex-
pressed by the same individual cell, and if this coexpression
might be of some significance for cell activation in vivo.
However, these results suggest that eosinophils might pro-
vide costimulation of T cells (specially type 2 cells) via
CD86, and conversely that they might respond to stimula-
tion via CD28 engagement.
In this study, only stimulation of the CD28 molecule,
not CD86 ligation, triggered cytokine release by highly pu-
rified human eosinophils. In contrast to CD28, able to pro-
vide a strong costimulatory signal on T cells, the main
function of CD86 is to bind to CD28 and not to act as a
signaling molecule in APCs, although the structure of the
cytoplasmic tail (three potential phosphorylation sites) indi-
cates a potential signaling role for this molecule (17). The
precise function of CD86 has yet to be investigated in
other pathways of eosinophil activation.
Although CD28 mainly participates in T cell activation
as a second signal, it has been recently shown that stimula-
tion through CD28 could induce early signaling events,
such as cytokine synthesis, in resting T cells, without fur-
ther requirement for TCR engagement (30). Experiments
are now in progress to investigate the patterns of signaling
events induced by CD28 activation of eosinophils.
An important outcome of this study is the release of type
1 cytokines by eosinophils after CD28 ligation, suggesting
that interactions between CD28-expressing eosinophils and
B7-expressing cells could induce previously unsuspected
functions of eosinophils in the immune response. Until
now, IL-2 was believed to be produced mainly by T lym-
phocytes. However, two groups recently reported the pro-
duction of IL-2 by human eosinophils, its storage in the
crystalloid granule, and IL-2 secretion after GM-CSF and
A23187 stimulation (10, 31). The fact that eosinophils can
produce IL-2 after CD28 ligation suggests that these cells
could induce lymphocyte activation and consequently sus-
tain the inflammatory processes, particularly in chronic dis-
eases associated with eosinophils, such as asthma, skin diseases,
or inflammatory bowel diseases. The release of biologically
active IFN-g by eosinophils, which has never been re-
ported, led us to speculate that eosinophils might exert an-
tiviral properties, and prompted consideration of strategies
aiming toward the demonstration of this new effector func-
tion of eosinophils in innate as well as acquired immunity.
Although at this stage it is not possible to draw definitive
Figure 6. Reciprocal effect of
IgA–anti-IgA complexes and
CD28 on IL-10, IL-2, and IFN-g
release. Purified eosinophils (2 3
106/ml) were stimulated with ei-
ther immobilized anti-CD28
mAb, IgA–anti-IgA, or IgA fol-
lowed by anti-IgA together with
immobilized anti-CD28 as de-
scribed in Materials and Meth-
ods. After 18 h, supernatants
were harvested and analyzed by
ELISA for cytokine content.
Data were obtained from three
different patients (Table I, do-
nors 18, 20, and 21) and are pre-
sented as mean 6 SEM.494 CD28-mediated Release of IL-2 and IFN-g by Eosinophils
conclusions about the mechanism of inhibition of the
CD28-dependent activation induced by secretory IgA–
anti-IgA complexes, our results indicating that activation
with secretory IgA but not with anti-CD28 could induce
the release of IL-10, a potent inhibitory cytokine of the
Th1 pathway, suggest the existence of cross-regulatory sig-
nals involved in the release of type 1 versus type 2 cyto-
kines by eosinophils. Further experiments are needed to
elucidate the precise role of IL-10 in this mechanism and
the possible intervention of IL-10 receptor expressed by
eosinophils. Interestingly, the inhibitory role of IL-10 on
eosinophil activation as well as its role in the decrease of type
1 cytokine production by T cells have already been reported
(for a review, see reference 32). Thus, it will be of interest
to investigate whether this inhibitory function of secretory
IgA on the CD28-mediated release of type 1 cytokines,
which would favor the Th2-mediated response, could be
also detected for other cell populations, such as T cells, and
whether it could play a role in the low dose oral tolerance
phenomenon or other clinically relevant disease situations.
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